Pomerantz Law Firm Files Class Action Against PROCEPT BioRobotics Over Alleged Securities Fraud

Investor Alert: Class Action Filed Against PROCEPT BioRobotics Corporation

Pomerantz LLP has taken significant action regarding investor losses in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by filing a class action lawsuit. This lawsuit comes amidst allegations that the company and certain of its executives may have mismanaged the business, leading to substantial losses for its investors.

Overview of the Lawsuit

The Pomerantz Law Firm encourages any investors who have suffered losses related to PROCEPT BioRobotics shares to reach out. Interested parties must act quickly, as the deadline to request lead plaintiff status is September 22, 2026. This lawsuit specifically revolves around potential securities fraud and other illegal business practices that may have harmed shareholders.

Early this summer, Pomerantz announced the filing, which highlights various troubling trends seen within the company’s financial disclosures. Investors who acquired shares during the class period are particularly urged to answer an urgent call for action. Those with inquiries can reach Danielle Peyton at (646) 581-9980 or via email, provided they include important contact details and specifics on their shares.

Financial Missteps and Market Reaction

The culmination of investor distress traces back to PROCEPT's disappointing performance metrics. Reports revealed troubling sales figures, with only 12,750 handpieces sold in the second fiscal quarter of 2025. Expectations had been previously set higher, defining an alarming discrepancy between projections and reality that led to a significant downturn in stock value, plunging by approximately 16% in just two days.

During the earnings call, Chief Financial Officer Kevin Waters lowered the sales forecast for the approaching quarter beneath market anticipations, further exacerbating investor discontent. Additionally, the abrupt restructuring, including pulling the plug on the role of Chief Commercial Officer, raises questions about the company’s internal strategies to combat its declining position.

As additional financial results were announced in subsequent months, further missteps became apparent. PROCEPT struggled with inventory management, leading to yet another decline in stock value—over 10% in relation to its third-quarter outcomes.

Most recently, PROCEPT’s fourth-quarter figures provided no respite. Sales were declared substantially below expectations, revealing an alarming drop from 13,225 units to just 9,400 units. This staggering nearly 30% decrease showcased the brand's inability to regain strength, leading to a further stock depreciation exceeding 18% across the same two-day trading window.

Pomerantz’s Commitment to Justice

With over 85 years of tradition in class action litigation, Pomerantz LLP stands as a champion for those wronged in the corporate sphere. This class action marks the firm’s ongoing commitment to uphold investor rights and pursue justice for victims of corporate misconduct. The firm has successfully secured numerous multimillion-dollar settlements for affected shareholders in past cases, highlighting its established reputation in financial litigation.

Interested investors are encouraged to act promptly considering the approaching deadlines, emphasizing that prior results do not guarantee similar outcomes. This lawsuit not only serves as a beacon for investors but as a potential paradigm shift for corporate accountability in the securities landscape.

For more specific details, stakeholders are urged to consult with Pomerantz to explore their options and safeguard their financial interests against potential corporate wrongdoing.